SI2827863T1 - Tekoči sestavek za uporabo v postopku zdravljenja odzivnih stanj na bendamustin v pacientih, pri katerih so potrebni zmanjšani vnosi za administracijo - Google Patents

Tekoči sestavek za uporabo v postopku zdravljenja odzivnih stanj na bendamustin v pacientih, pri katerih so potrebni zmanjšani vnosi za administracijo

Info

Publication number: SI2827863T1
Authority: SI; Slovenia
Prior art keywords: administration; liquid composition; patients requiring; requiring reduced; reduced volumes
Prior art date: 2012-03-20

Application number

SI201331394T

Other languages

English (en)

Inventor

Srikanth Sundaram

Scott L. Tarriff

Original Assignee

Eagle Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-20

Filing date

2013-03-15

Publication date

2019-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2827863(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-15 Application filed by Eagle Pharmaceuticals, Inc. filed Critical Eagle Pharmaceuticals, Inc.

2019-06-28 Publication of SI2827863T1 publication Critical patent/SI2827863T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

SI201331394T 2012-03-20 2013-03-15 Tekoči sestavek za uporabo v postopku zdravljenja odzivnih stanj na bendamustin v pacientih, pri katerih so potrebni zmanjšani vnosi za administracijo SI2827863T1 (sl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261613173P	2012-03-20	2012-03-20
US201261669889P	2012-07-10	2012-07-10
US201261678715P	2012-08-02	2012-08-02
EP13765020.6A EP2827863B1 (en)	2012-03-20	2013-03-15	Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
PCT/US2013/032295 WO2013142359A1 (en)	2012-03-20	2013-03-15	Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration

Publications (1)

Publication Number	Publication Date
SI2827863T1 true SI2827863T1 (sl)	2019-06-28

Family

ID=49212373

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201332039T SI3533447T1 (sl)	2012-03-20	2013-03-15	Tekoči sestavki bendamustina za uporabo v postopku zdravljenja na bendamustin odzivnih stanj pri bolnikih,pri katerih so potrebni zmanjšani volumni za dajanje
SI201331394T SI2827863T1 (sl)	2012-03-20	2013-03-15	Tekoči sestavek za uporabo v postopku zdravljenja odzivnih stanj na bendamustin v pacientih, pri katerih so potrebni zmanjšani vnosi za administracijo

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI201332039T SI3533447T1 (sl)	2012-03-20	2013-03-15	Tekoči sestavki bendamustina za uporabo v postopku zdravljenja na bendamustin odzivnih stanj pri bolnikih,pri katerih so potrebni zmanjšani volumni za dajanje

Country Status (17)

Country	Link
US (3)	US9000021B2 (sl)
EP (3)	EP2827863B1 (sl)
JP (6)	JP6224064B2 (sl)
CN (2)	CN104271135B (sl)
CA (1)	CA2867343C (sl)
DK (2)	DK2827863T3 (sl)
ES (2)	ES2943668T3 (sl)
FI (1)	FI3533447T3 (sl)
HK (1)	HK1243346A1 (sl)
HR (2)	HRP20230276T1 (sl)
HU (2)	HUE062230T2 (sl)
LT (1)	LT2827863T (sl)
PL (2)	PL3533447T3 (sl)
PT (2)	PT3533447T (sl)
RS (2)	RS64137B1 (sl)
SI (2)	SI3533447T1 (sl)
WO (1)	WO2013142359A1 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2528602T5 (pl)	2010-01-28	2020-09-07	Eagle Pharmaceuticals, Inc.	Preparaty bendamustyny
DK2827862T3 (da) *	2012-03-20	2024-02-12	Eagle Pharmaceuticals Inc	Formuleringer af bendamustin
WO2013142359A1 (en)	2012-03-20	2013-09-26	Eagle Pharmaceuticals, Inc.	Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US20230241218A1 (en) *	2012-07-10	2023-08-03	Eagle Pharmaceuticals, Inc.	Formulations of bendamustine
US11826466B2 (en)	2016-08-31	2023-11-28	Navinta, Llc	Bendamustine solution formulations
US10905677B2 (en)	2016-08-31	2021-02-02	Navinta, Llc	Bendamustine solution formulations
WO2020035806A1 (en)	2018-08-17	2020-02-20	Hospira Australia Pty Ltd	Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) *	2018-11-26	2023-08-22	Good Health, Llc	Stable liquid pharmaceutical compositions comprising bendamustine
JP7235288B2 (ja) *	2019-01-07	2023-03-08	コーアイセイ株式会社	ベンダムスチンの液体製剤
CN110123747A (zh) *	2019-04-26	2019-08-16	嘉兴市爵拓科技有限公司	苯达莫司汀的制剂
JPWO2021014957A1 (sl) *	2019-07-22	2021-01-28
JPWO2021161876A1 (sl) *	2020-02-10	2021-08-19
US20240148696A1 (en)	2022-10-25	2024-05-09	Softkemo Pharma Inc.	Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE159289C (sl)	1903-10-08	1905-03-16
US4071620A (en)	1977-01-10	1978-01-31	American Home Products Corporation	Stabilization of oxygen sensitive dose forms
DD159289A1 (de)	1981-06-01	1983-03-02	Uwe Olthoff	Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de)	1984-12-21	1986-07-10	Merckle Gmbh	Fluessige diclofenac-zubereitungen
US5223515A (en)	1988-08-18	1993-06-29	Takeda Chemical Industries, Ltd.	Injectable solution containing a pyridyl methylsulfinylbenzimidazole
CA2181241C (en)	1994-01-24	2000-04-25	Dadi Jamshed Dhabhar	Process for solubilizing difficultly soluble pharmaceutical actives
ATE526022T1 (de)	1998-04-20	2011-10-15	Eisai R&D Man Co Ltd	Stabilisierte zusammenstellungen die benzimidazole enthalten
AU2001211213A1 (en)	2000-10-20	2002-04-29	Galephar M/F	Stable oral formulation containing benzimidazole derivative
AR040693A1 (es)	2002-07-30	2005-04-13	Wyeth Corp	Formulaciones parenterales
US20060035945A1 (en)	2003-05-30	2006-02-16	Giorgio Attardo	Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
SE0401842D0 (sv) *	2004-07-12	2004-07-12	Dizlin Medical Design Ab	Infusion and injection solution of levodopa
JP2008519047A (ja)	2004-11-05	2008-06-05	セフアロン・インコーポレーテツド	癌処置
US8436190B2 (en)	2005-01-14	2013-05-07	Cephalon, Inc.	Bendamustine pharmaceutical compositions
WO2007026771A1 (ja) *	2005-08-31	2007-03-08	Ono Pharmaceutical Co., Ltd.	点滴用注射剤
AU2007285215A1 (en)	2006-08-14	2008-02-21	Eisai R & D Management Co., Ltd.	Stable lyophilized preparation
US8277807B2 (en)	2006-10-12	2012-10-02	Astex Therapeutics Limited	Pharmaceutical combinations
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
DE102007003184A1 (de)	2007-01-22	2008-07-24	Orlowski, Michael, Dr.	Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en)	2007-09-25	2009-03-26	Protia, Llc	Deuterium-enriched bendamustine
AR072777A1 (es)	2008-03-26	2010-09-22	Cephalon Inc	Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) *	2008-09-25	2015-07-01	Cephalon, Inc.	Liquid formulations of bendamustine
KR20110110293A (ko)	2009-01-15	2011-10-06	세파론, 인코포레이티드	벤다무스틴 유리 염기의 신규 형태
RU2591804C2 (ru)	2009-02-25	2016-07-20	Супратек Фарма, Инк.	Композиции бендамустина и циклополисахарида
US20100273730A1 (en) *	2009-04-27	2010-10-28	Innopharmax, Inc.	Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
EP2424506A1 (en)	2009-04-28	2012-03-07	Cephalon, Inc.	Oral formulations of bendamustine
WO2010148288A2 (en)	2009-06-19	2010-12-23	Lyotropic Therapeutics, Inc.	Pharmaceutical formulations with low aqueous levels of free unbound drug
CN101584668A (zh) *	2009-06-19	2009-11-25	江苏奥赛康药业有限公司	盐酸苯达莫司汀冻干粉针剂
US8389558B2 (en)	2009-07-20	2013-03-05	Supratek Pharma Inc.	Bendamustine amphiphilic anionic compositions
US20110015245A1 (en)	2009-07-20	2011-01-20	Valery Alakhov	Bendamustine amphiphilic cationic compositions
US7772274B1 (en)	2009-10-19	2010-08-10	Scidose, Llc	Docetaxel formulations with lipoic acid
PL2528602T5 (pl) *	2010-01-28	2020-09-07	Eagle Pharmaceuticals, Inc.	Preparaty bendamustyny
ES2593256T3 (es)	2010-05-21	2016-12-07	Infinity Pharmaceuticals, Inc.	Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CA2804855A1 (en)	2010-07-28	2012-02-02	Eagle Pharmaceuticals, Inc.	Pharmaceutical compositions containing pemetrexed having extended storage stability
AU2012347972B2 (en)	2011-12-05	2018-05-10	X-Body, Inc.	PDGF receptor beta binding polypeptides
US20130210878A1 (en) *	2012-01-24	2013-08-15	Innopharma, Inc.	Bendamustine compositions and methods therefore
WO2013123227A1 (en)	2012-02-14	2013-08-22	Eagle Pharmaceuticals, Inc.	Formulations of bendamustine
WO2013142359A1 (en)	2012-03-20	2013-09-26	Eagle Pharmaceuticals, Inc.	Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
DK2827862T3 (da)	2012-03-20	2024-02-12	Eagle Pharmaceuticals Inc	Formuleringer af bendamustin

2013
- 2013-03-15 WO PCT/US2013/032295 patent/WO2013142359A1/en active Application Filing
- 2013-03-15 PL PL19151152.6T patent/PL3533447T3/pl unknown
- 2013-03-15 HU HUE19151152A patent/HUE062230T2/hu unknown
- 2013-03-15 PL PL13765020T patent/PL2827863T3/pl unknown
- 2013-03-15 EP EP13765020.6A patent/EP2827863B1/en active Active
- 2013-03-15 DK DK13765020.6T patent/DK2827863T3/en active
- 2013-03-15 CN CN201380023660.5A patent/CN104271135B/zh not_active Expired - Fee Related
- 2013-03-15 DK DK19151152.6T patent/DK3533447T3/da active
- 2013-03-15 HU HUE13765020 patent/HUE044233T2/hu unknown
- 2013-03-15 PT PT191511526T patent/PT3533447T/pt unknown
- 2013-03-15 LT LTEP13765020.6T patent/LT2827863T/lt unknown
- 2013-03-15 JP JP2015501814A patent/JP6224064B2/ja active Active
- 2013-03-15 HR HRP20230276TT patent/HRP20230276T1/hr unknown
- 2013-03-15 ES ES19151152T patent/ES2943668T3/es active Active
- 2013-03-15 SI SI201332039T patent/SI3533447T1/sl unknown
- 2013-03-15 RS RS20230252A patent/RS64137B1/sr unknown
- 2013-03-15 EP EP19151152.6A patent/EP3533447B1/en active Active
- 2013-03-15 US US13/838,267 patent/US9000021B2/en active Active
- 2013-03-15 PT PT13765020T patent/PT2827863T/pt unknown
- 2013-03-15 CA CA2867343A patent/CA2867343C/en active Active
- 2013-03-15 EP EP23161418.1A patent/EP4218756A1/en active Pending
- 2013-03-15 SI SI201331394T patent/SI2827863T1/sl unknown
- 2013-03-15 RS RS20190433A patent/RS58744B1/sr unknown
- 2013-03-15 CN CN201710292508.7A patent/CN107157988A/zh active Pending
- 2013-03-15 ES ES13765020T patent/ES2718902T3/es active Active
2014
- 2014-11-26 US US14/554,269 patent/US20150080444A1/en not_active Abandoned
2015
- 2015-03-15 FI FIEP19151152.6T patent/FI3533447T3/fi active
- 2015-08-06 US US14/820,291 patent/US9579384B2/en active Active
2017
- 2017-10-04 JP JP2017193917A patent/JP6381761B2/ja active Active
2018
- 2018-02-28 HK HK18102930.9A patent/HK1243346A1/zh unknown
- 2018-07-31 JP JP2018143022A patent/JP6738376B2/ja active Active
2019
- 2019-04-12 HR HRP20190693TT patent/HRP20190693T1/hr unknown
2020
- 2020-05-29 JP JP2020093802A patent/JP2020143143A/ja active Pending
2021
- 2021-11-17 JP JP2021186829A patent/JP2022028813A/ja active Pending
2023
- 2023-12-15 JP JP2023212014A patent/JP2024037915A/ja active Pending

Also Published As

Publication number	Publication date
DK3533447T3 (da)	2023-04-24
FI3533447T3 (fi)	2023-05-04
CN107157988A (zh)	2017-09-15
JP2020143143A (ja)	2020-09-10
HUE062230T2 (hu)	2023-10-28
RS64137B1 (sr)	2023-05-31
SI3533447T1 (sl)	2023-06-30
JP6381761B2 (ja)	2018-08-29
WO2013142359A1 (en)	2013-09-26
CN104271135A (zh)	2015-01-07
PT2827863T (pt)	2019-05-13
US20150343061A1 (en)	2015-12-03
PL2827863T3 (pl)	2019-07-31
HK1243346A1 (zh)	2018-07-13
EP2827863B1 (en)	2019-01-16
US9000021B2 (en)	2015-04-07
JP2022028813A (ja)	2022-02-16
EP4218756A1 (en)	2023-08-02
ES2718902T3 (es)	2019-07-05
PL3533447T3 (pl)	2023-07-17
EP3533447A1 (en)	2019-09-04
PT3533447T (pt)	2023-05-17
LT2827863T (lt)	2019-06-10
HUE044233T2 (hu)	2019-10-28
US9579384B2 (en)	2017-02-28
DK2827863T3 (en)	2019-04-23
JP6224064B2 (ja)	2017-11-01
ES2943668T3 (es)	2023-06-15
CA2867343C (en)	2020-08-11
JP2015510940A (ja)	2015-04-13
CN104271135B (zh)	2017-05-17
US20150080444A1 (en)	2015-03-19
RS58744B1 (sr)	2019-06-28
HRP20190693T1 (hr)	2019-10-04
EP2827863A1 (en)	2015-01-28
HRP20230276T1 (hr)	2023-04-28
EP2827863A4 (en)	2015-11-18
CA2867343A1 (en)	2013-09-26
JP2018197248A (ja)	2018-12-13
EP3533447B1 (en)	2023-03-15
JP2018048153A (ja)	2018-03-29
US20130253026A1 (en)	2013-09-26
JP2024037915A (ja)	2024-03-19
JP6738376B2 (ja)	2020-08-12

Publication	Publication Date	Title
HUE044233T2 (hu)	2019-10-28	Folyékony készítmény bendamusztinra reagáló állapotok kezelési eljárásban történõ alkalmazásra, ahol a betegek csökkentett térfogatú bevitelre szorulnak
IL249991A0 (en)	2017-03-30	Methods of treating sick children by dexmedetomidine
HK1194696A1 (zh)	2014-10-24	用於受控輸送醫用流體的系統
IL229474A0 (en)	2014-01-30	Cannabinoids for use in the treatment of neuropathic pain
EP2788075A4 (en)	2015-07-29	DEVICE AND METHOD FOR REDUCING THE TRANSTHORACOID IMPEDANCE OF A PATIENT
EP2670434A4 (en)	2015-11-11	TREATMENT OF TAUOPATHIA
PL2773648T3 (pl)	2020-03-31	Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile
PL2644215T3 (pl)	2015-04-30	Aparat do pozaustrojowej obróbki krwi
GB2523055B (en)	2015-12-09	Ophthalmic devices for delivery of beneficial agents
ES3009438T3 (en)	2025-03-26	Method and pharmaceutical composition for use in the treatment of cancer
HK1172569A1 (en)	2013-04-26	Chinese medicine composition for treating colds and preparation method thereof
GB201218084D0 (en)	2012-11-21	Novel compounds and methods for use in medicine
EP2832434A4 (en)	2015-02-25	METHOD FOR TREATING SIMULTANEOUS CAVITATION OF LIQUID MEDIA OF DIFFERENT COMPOSITIONS
HRP20180011T1 (hr)	2018-02-23	Spojevi za uporabu u liječenju filariaza
GB2508897B (en)	2016-02-10	Oxygen flow controller for medical use
IL231531A (en)	2017-02-28	Use of strigolactones and their analogues for the preparation of drugs for the treatment of cancerous growth conditions
GB201209283D0 (en)	2012-08-15	Liquid treatment
GB201209198D0 (en)	2012-07-04	Liquid treatment
HUP1100245A2 (en)	2012-11-28	Pharmaceutical composition for the treatment of wounds
PH32012000869S1 (en)	2015-04-15	Containing and applying tool for liquid medicine